

ClinGen Myeloid Malignancy Variant Curation Expert Panel COI						
Date	Your Name	Do you work for a laboratory that offers fee-for-service testing related to the work of your Expert Panel?	Have you made substantial contributions to the literature implicating a gene:disease relationship that relates to the work of your Expert		Do you have any other existing or planned independent curation efforts that will potentially overlap with the scope of your ClinGen work? If so, please describe:	Please disclose any other relevant conflicts of interest (e.g. patents, intellectual property ownership, or paid consultancies related to any variants or genes associated with the work of your Expert Panel):
	Open-Ended Response	Response	Response	If yes, please list the genes:	Open-Ended Response	Open-Ended Response
2019-02-22 15:58:04	Daniel E. Pineda-Alvarez	Yes	Yes	Upcoming CNV interpretation guidelines to be published as a joint ClinGen/ACMG effort	Yes, dosage sensitivity curation	none

					Working on a manuscript for a somatic curation process, which is mainly based on my experience performing curation for a myeloid malignancy panel for patients who have a cancer diagnosis (purpose is prognostication and therapeutic recommendation - not really a test to gauge hereditary	
2019-01-19 15:36:11	Nikita Mehta	Yes	No			None that I am aware of.
2019-01-14 17:00:14	Simone Feurstein	No	No		There is no overlapping curation effort.	There are no conflict of interest.
2018-07-11 14:46:59	Shruthi Mohan	No	No		No.	No conflicts of interest.
2018-06-19 23:50:19	Liyang Zhang	No	No		No.	N/A
2018-06-02 11:19:11	Panagiotis Baliakas	Yes	No		NO	
2018-04-25 18:13:17	Minjie Luo	No	No		No	NO

2018-03-30 11:57:59	Michael Walsh	No	Yes		At MSK we have an integrative Tumor board meeting and review of germline variants. This process overlaps with ClonGen work.	I have nothing to disclose. MSK Clinical Genetics service has developed a variant culling tool called PathoMan for which I've provide intellectual input.
2018-03-29 18:31:28	Anna Brown	Yes	Yes	DDX41	Yes. A database of sequence information from germline RUNX1 mutated tumours, which will include curation of variants.	
2018-03-29 11:56:53	Mark Routbort	Yes	No		I curate mutations internally at MD Anderson as part of our laboratories reporting workflow. This is primarily related to somatic mutations in leukemia and lymphoma.	
2018-03-28 18:27:56	Sharon Plon	No	Yes	(1) whole gene deletions for RUNX1 and FPD/AML, and the PAX5 - familial ALL connection.	No.	Member, Scientific Advisory Panel of Baylor Genetics Laboratories.

2018-03-28 6:23:08	sioban keel	No	Yes	ETV6	No	None.
2018-03-28 4:10:58	Tom Vulliamy	No	Yes	TERT TERT GATA2 SRP72 DDX41	No, only the database I curate for private use	
2018-03-28 3:55:37	Jean Soulier	No	Yes	SAMD9, SAMD9L, MECOM, ERCC6L2	No	No disclosure
2018-03-28 3:16:00	Raimbault	Yes	Yes	SAMD9 SAMD9L		
2018-03-27 21:58:24	Lesley Rawlings	Yes	No		No	
2018-03-27 18:15:57	Alison Bertuch	No	Yes	It may not be considered substantial but I have published on TERT, GATA2, SBDS, and TINF2.	No	
2018-03-27 16:09:23	Courtney DiNardo	No	No		no	none
2018-03-27 15:15:58	Christopher Porter	No	Yes	ETV6	No.	
2018-03-27 10:13:59	Anupriya Agarwal	No	No		We will be curating the BEAT AML whole exome sequencing data for germline mutations.	Have funding from CTI for performing a preclinical study with Pacritinib in AML
2018-03-27 10:22:46	Shannon McWeeney	No	No			None related
2018-03-26 12:06:31	Ying Wang	Yes	No		No	No

2018-03-26 9:38:21	Gabriella Ryan	No	No		I am the Project Manager for the effort whereby the American Society of Hematology is sponsoring two Expert Panels. I am not directly involved with curation.	
2018-03-23 22:41:41	Chimene Kesserwan	No	No		No	
2018-03-23 13:17:38	David Wu	Yes	No		Not planned	No other financial conflicts. I receive a state salary for my professional services as a pathologist. Part of my clinical duties involve the review and sign-out of bone marrow failure / hereditary AML/MDS testing by next-generation sequencing. I do not receive any royalties, do not have patents, nor any other financial benefit in this regard.
2018-03-23 11:04:16	Mark Fleming	No	No		NO	
2018-03-23 11:02:47	Zejuan Li	Yes	No		No	No

2018-03-23 10:56:44	Sarah A Jackson	Yes	No		I evaluate genes for disease associations and classify variants for a clinical commercial genetic testing company.	n/a
2018-03-23 9:51:59	Michael Chicka	Yes	No		No	I have no other conflicts of interest
2018-03-23 8:53:50	Luca Malcovati	No	No			No conflicts of interest to disclose
2018-03-23 8:43:20	Kim Nichols	No	Yes	I published on germline mutations in ETV6 and their role in Thrombocytopenia 5.	no	none
2018-03-23 8:36:08	Justyne Ross	No	No			
2018-03-23 7:15:40	Lucy Godley	No	Yes	RUNX1, DDX41, TERT; reviews on all of the genes that confer germline susceptibility	no	I get paid royalties from a review article that I co-wrote for UpToDate, Inc.
2018-03-19 14:26:39	Xi Luo	No	No		No	No

